Certara, provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, announced that it has acquired d3 Medicine. d3 Medicine, which is based in Parsippany, NJ and Melbourne, Australia, provides strategic planning and stewardship of complex drug development programs.
d3 Medicine staff will become part of Certara's Strategic Consulting (CSC) division, which was formed in July 2015 through the merger of Quantitative Solutions and Pharsight Consulting Services. CSC is the largest consultancy of its kind; it now has more than 100 scientists, the majority with PhDs, using a broad range of modeling and simulation methods and technologies to support global sponsors in bringing new therapies to patients.
Also read: Allergan acquires gene therapy start-up
"d3 Medicine's addition to Certara continues to strengthen our ability to provide our clients with optimized and strategic drug development plans that leverage our unique modeling and simulation, and regulatory advisory and communications expertise," said Certara Chief Executive Officer (CEO) Edmundo Muniz, MD, PhD.
The addition of d3 Medicine provides Certara with expanded capabilities and expertise, most notably in the areas of oncology, orphan diseases, infectious diseases and inflammation, including:
• drug development optimization strategy, stewardship and implementation,
• regulatory consulting and liaison services with global health authorities, and
• pressure testing and optimizing licensing and M&A plans.
"We are thrilled to be joining Certara, the most innovative and seasoned modeling and simulation drug development company in the world," said Craig Rayner, PharmD, MBA, CEO of d3 Medicine.
Financial details about the transaction were not disclosed.
